Irland - engelsk - HPRA (Health Products Regulatory Authority)

wockhardt uk limited - ceftazidime - powder for solution for injection/infusion - 1 gram(s) - third-generation cephalosporins; ceftazidime

Irland - engelsk - HPRA (Health Products Regulatory Authority)

wockhardt uk limited - ceftazidime - powder for solution for injection/infusion - 2 gram(s) - third-generation cephalosporins; ceftazidime

Irland - engelsk - HPRA (Health Products Regulatory Authority)

hikma farmacêutica (portugal) s.a. - ceftazidime - powder for solution for injection/infusion - 1 gram(s) - third-generation cephalosporins; ceftazidime

Irland - engelsk - HPRA (Health Products Regulatory Authority)

hikma farmacêutica (portugal) s.a. - ceftazidime - powder for solution for injection/infusion - 2 gram(s) - third-generation cephalosporins; ceftazidime

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - ceftazidime pentahydrate, quantity: 1175 mg (equivalent: ceftazidime, qty 1000 mg) - injection, powder for - excipient ingredients: sodium carbonate - ceftazidime for injection is indicated for the treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not to ceftazidime, and as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other pseudomonal antibiotics cannot be used. ,indications include the following:,severe infections in general: ,for example: septicaemia including neonatal sepsis, bacteraemia; and in patients in intensive care units with specific problems, e.g., infected burns.,respiratory tract infections: ,for example: pneumonia, broncho-pneumonia, infected pleurisy, infected bronchiectasis and bronchitis.,severe ear, nose and throat infections: ,for example: otitis media, mastoiditis.,urinary tract infections: ,for example: acute and chronic pyelonephritis, pyelitis, cystitis, urethritis (bacterial only), and infections associated with bladder and renal stones.,skin and soft tissue infections: ,for example, erysipelas, abscesses, cellulitis, infected burns and wounds, mastitis.,gastrointestinal and abdominal infections: ,for example: intra-abdominal abscesses, enterocolitis.,bone and joint infections: ,for example: osteitis, osteomyelitis, septic arthritis, infected bursitis.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - ceftazidime pentahydrate, quantity: 2349 mg (equivalent: ceftazidime, qty 2000 mg) - injection, powder for - excipient ingredients: sodium carbonate - ceftazidime for injection is indicated for the treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not to ceftazidime, and as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other pseudomonal antibiotics cannot be used. ,indications include the following:,severe infections in general: ,for example: septicaemia including neonatal sepsis, bacteraemia; and in patients in intensive care units with specific problems, e.g., infected burns.,respiratory tract infections: ,for example: pneumonia, broncho-pneumonia, infected pleurisy, infected bronchiectasis and bronchitis.,severe ear, nose and throat infections: ,for example: otitis media, mastoiditis.,urinary tract infections: ,for example: acute and chronic pyelonephritis, pyelitis, cystitis, urethritis (bacterial only), and infections associated with bladder and renal stones.,skin and soft tissue infections: ,for example, erysipelas, abscesses, cellulitis, infected burns and wounds, mastitis.,gastrointestinal and abdominal infections: ,for example: intra-abdominal abscesses, enterocolitis.,bone and joint infections: ,for example: osteitis, osteomyelitis, septic arthritis, infected bursitis.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - ceftazidime pentahydrate, quantity: 1164.8 mg (equivalent: ceftazidime, qty 1000 mg) - injection, powder for - excipient ingredients: sodium carbonate - treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not to ceftazidime; as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other antipseudomonal antibiotics cannot be used. indications include the folowing: severe infections in general (e.g. septicaemia including neonatal sepsis, bacteraemia; in patients in intensive care units with specific problems, e.g. infected burns). respiratory tract (e.g. pneumonia, bronchopneumonia, infected pleurisy, infected bronchiectasis and bronchitis). severe ear, nose and throat infections (e.g. otitis media, mastoiditis). urinary tract (e.g. acute and chronic pyelonephritis, pyelitis, cystitis - bacterial only; infections associated with bladder and renal stones). skin and soft tissue (e.g. erysipelas abscesses, cellulitis, infected burns and wounds, mastitis). gastrointestinal and abdominal (e.g. intra-abdominal abscesses, enterocolitis). bone and joint (e.g. osteitis, osteomyelitis, septic arthritis, infected burstis).

USA - engelsk - NLM (National Library of Medicine)

sandoz inc - ceftazidime (unii: 9m416z9qnr) (ceftazidime anhydrous - unii:dzr1ent301) - ceftazidime for injection, usp is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: ceftazidime for injection, usp may be used alone in cases of confirmed or suspected sepsis. ceftazidime has been used successfully in clinical trials as empiric therapy in cases where various concomitant therapies with other antibiotics have been used. ceftazidime for injection, usp may also be used concomitantly with other antibiotics, such as aminoglycosides, vancomycin, and clindamycin; in severe and life-threatening infections; and in the immunocompromised patient. when such concomitant treatment is appropriate, prescribing information in the labeling for the other antibiotics should be followed. the dose depends on the severity of the infection and the patient’s condition. to reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftazidime for injection, usp and other antibacterial drugs, ceftazidime f

USA - engelsk - NLM (National Library of Medicine)

sagent pharmaceuticals - ceftazidime (unii: 9m416z9qnr) (ceftazidime anhydrous - unii:dzr1ent301) - ceftazidime for injection, usp is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: - lower respiratory tract infections, including pneumonia, caused by pseudomonas aeruginosa and other pseudomonas spp.; haemophilus influenzae, including ampicillin-resistant strains; klebsiella spp.; enterobacter spp.; proteus mirabilis; escherichia coli; serratia spp.; citrobacter spp.; streptococcus pneumoniae; and staphylococcus aureus (methicillin-susceptible strains). - skin and skin-structure infections caused by pseudomonas aeruginosa; klebsiella spp.; escherichia coli; proteus spp., including proteus mirabilis and indole-positive proteus; enterobacter spp.; serratia spp.; staphylococcus aureus (methicillin-susceptible strains); and streptococcus pyogenes (group a beta-hemolytic streptococci). - urinary tract infections, both complicated and uncomplicated, caused by pseudomonas aeruginosa; enterobacter s

USA - engelsk - NLM (National Library of Medicine)

sagent pharmaceuticals - ceftazidime (unii: 9m416z9qnr) (ceftazidime anhydrous - unii:dzr1ent301) - ceftazidime for injection, usp is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: - lower respiratory tract infections, including pneumonia, caused by pseudomonas aeruginosa and other pseudomonas spp.; haemophilus influenzae, including ampicillin-resistant strains; klebsiella spp.; enterobacter spp.; proteus mirabilis; escherichia coli; serratia spp.; citrobacter spp.; streptococcus pneumoniae; and staphylococcus aureus (methicillin-susceptible strains). - skin and skin-structure infections caused by pseudomonas aeruginosa; klebsiella spp.; escherichia coli; proteus spp., including proteus mirabilis and indole-positive proteus; enterobacter spp.; serratia spp.; staphylococcus aureus (methicillin-susceptible strains); and streptococcus pyogenes (group a beta-hemolytic streptococci). - urinary tract infections, both complicated and uncomplicated, caused by pseudomonas aeruginosa; enterobacter spp.; pr